Buprenorphine transdermal - Mundipharma

Drug Profile

Buprenorphine transdermal - Mundipharma

Alternative Names: BTDS; BuTrans; Butrans; Butrans Transdermal System CIII; Norspan; Norspan Tape; Restive; Sovenor

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Mundipharma International
  • Developer Grunenthal; Hisamitsu Pharmaceutical; Mundipharma International; Purdue Pharma
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 26 Sep 2016 Pharmacokinetics data from a phase I trial in Pain (In volunteers) presented at the 16th World Congress on Pain (WCP-2016)
  • 01 Apr 2016 Purdue Pharma completes a phase III trial (In children, In adolescents) in Pain in USA (NCT01324570)
  • 01 Nov 2015 Mundipharma completes a phase I trial in Healthy volunteers in United Kingdom (NCT02431624)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top